Drug Topics

MARCH 21, 2024

Researchers collected data to measure inequities in pharmacy access across the country.

211

211

STAT

MARCH 21, 2024

In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday that, for the first time, it had transplanted a kidney from a CRISPR gene-edited pig into a living patient. Surgeons performed the milestone procedure over four hours on Saturday, March 16, without complications. As of Thursday morning, the organ recipient, a 62-year-old man named Richard Slayman, was “recovering well” and expected to be discharged soon, the hospital said in a

Hospitals 145

Hospitals 145

Drug Topics

MARCH 21, 2024

Farmers and welders have adapted to work with the current times. Pharmacists should consider adapting their profession as well.

181

181

Fierce Healthcare

MARCH 21, 2024

More than 100 provider organizations want the Centers for Medicare & Medicaid Services (CMS) to take a tougher stance on Medicare Advantage (MA) plans’ practices following an industry survey es | Providers spent nearly $20 billion in 2022 pursuing delays and denials across all payer types, yet those efforts are substantially more costly on average when dealing with private plans, hundreds of hospitals and health systems told Premier in a recent survey.

Hospitals 144

Hospitals 144

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

MARCH 21, 2024

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

FDA 153

FDA 153

STAT

MARCH 21, 2024

Early data regarding the use of GLP-1 medications like Ozempic and Wegovy to treat addiction is “very, very, exciting,” Nora Volkow, the director of the National Institute on Drug Abuse, said Thursday. But even as she expressed enthusiasm for the new drugs’ potential, Volkow criticized pharmaceutical companies for neglecting a moral imperative to develop new addiction treatments — but acknowledged that the health system more broadly doesn’t incentivize drug com

Pharmaceutical Companies 144

Pharmaceutical Companies Pharmaceutical Companies 144

STAT

MARCH 21, 2024

CRISPR is no longer a promising but unproven technology — it is a reality. But for this powerful gene-editing tool to reach its full potential, researchers and disease advocates say they’ll have to solve a thorny problem: connecting patients suffering from devastating diseases with therapies that could help them. Experts pointed to lab-developed tests, or LDTs, as one important element that could help make this connection during a panel at the STAT Breakthrough Summit East in New Y

141

141

Pharmacy Times

MARCH 21, 2024

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.

139

139

STAT

MARCH 21, 2024

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday. The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

139

139

Pharmacy Times

MARCH 21, 2024

The FDA has only approved aprocitentan (Tryvio; Idorsia) in the 12.5 mg dosage as the effects were similar between the 25 mg and 12.5 mg dosages.

FDA 138

FDA Dosage 138

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

MARCH 21, 2024

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

137

137

Fierce Healthcare

MARCH 21, 2024

Chipmaker Nvidia sees big opportunities in healthcare AI and this week it launched more than two dozen new gen AI-powered microservices. | The global computing powerhouse inked collaborations with Abridge, Microsoft, GE HealthCare and Hippocratic AI to to expand its generative AI capabilities into healthcare and life sciences.

133

133

STAT

MARCH 21, 2024

George Yancopoulos is in touch with his teenage self. After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

135

135

Pharmacy Times

MARCH 21, 2024

Merck will also conduct clinical trials in both males and females to evaluate the efficacy of a single dose of their current human papillomavirus vaccine compared with the approved 3-dose regimen.

Vaccines 132

Vaccines 132

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

MARCH 21, 2024

As more states create dedicated boards to cap the costs of medicines, some drugmakers and their allies are pushing back with a controversial tactic — lobbying for legislation to set exemptions for so-called orphan drugs, which are used to combat rare diseases that afflict relatively small groups of patients. The efforts, which are being joined by some some lawmakers, reflect concerns that patients may lose access to these medicines if pharmaceutical companies halt sales or decide not to i

Pharmaceutical Companies 131

Pharmaceutical Companies Pharmaceutical Companies 131

Pharmacy Times

MARCH 21, 2024

The BLA includes all indications for Xolair, including asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergy, and chronic spontaneous urticaria.

132

132

STAT

MARCH 21, 2024

The adverse childhood experience (ACE) questionnaire has become a critical part of public health. It offers physicians a screening tool to evaluate patients, gaining valuable insights into their physical and mental well-being. This information guides the implementation of preventive measures like lifestyle counseling to reduce the risk of ACE-related chronic conditions like depression, obesity, asthma, diabetes, and cancer.

130

130

Pharmacy Is Right For Me

MARCH 21, 2024

Inspired by a father who paved the way as a director of pharmacy, Dr. Jason Vinson knew from an early age what he wanted to do. Yet, it wasn’t until he walked the halls of hospitals during his undergraduate years at the University of Michigan that the allure of pharmacy truly took root. From the humble beginnings of a pharmacy messenger, delivering medications to patients, to the intricate process of making medications as a compounding technician, each step solidified his decision to pursu

Hospitals 130

Hospitals Community Pharmacies Compounding 130

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

MARCH 21, 2024

What happens after you close a nearly $11 billion acquisition? Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future. Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer.

Immunization 129

Immunization 129

pharmaphorum

MARCH 21, 2024

There is no denying that artificial intelligence (AI) has captured the imagination of innovators working across the pharmaceutical sector. The drug discovery space is no different, with myriad applications promising to revolutionise the way that researchers and sponsors approach identifying and progressing new drug candidates.

126

126

STAT

MARCH 21, 2024

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders. But now, a decade later, Editas is seen as lagging behind its peers.

129

129

pharmaphorum

MARCH 21, 2024

On today’s podcast, host Jonah Comstock is joined by Meri Beckwith, co-founder of Lindus Health, a next-gen CRO that includes digital therapeutics among its specialties. They talk a little bit about the often unseen difficulties of validating a digital therapeutic through a clinical trial.

124

124

STAT

MARCH 21, 2024

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

124

124

Fierce Pharma

MARCH 21, 2024

Drug developers often try to spot tidbits of positive information from a failed clinical trial. | Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its positive Enspryng study in the competitive autoimmune disorder of myasthenia gravis.

119

119

STAT

MARCH 21, 2024

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech.

117

117

pharmaphorum

MARCH 21, 2024

Novartis-supported multiple research project will use Seqster's data-sharing platform to support R&D and evidence-based care

115

115

STAT

MARCH 21, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with yet another megaround in biotech, a preview of some hotly anticipated data, and the perils of declining revenue.

116

116

pharmaphorum

MARCH 21, 2024

The rising demand for mono-material packaging in the pharmaceutical industry due to its sustainability benefits will have a significant impact. Learn more about how this trend is shaping the future of pharmaceutical packaging.

Packaging 115

Packaging 115

STAT

MARCH 21, 2024

Is there a cure for allergies? Has the FDA become too flexible? And which drugs make you muscular? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos.

FDA 113

FDA 113

Hospital Pharmacy Europe

MARCH 21, 2024

Supporting the successful compounding of drugs with 3D printing processes has the potential to not only fulfil unmet patient needs but also drive efficiencies in hospital pharmacies. Ian Soulairol from the Institut Charles Gerhardt Montpellier at Montpellier University and pharmacist at the Department of Pharmacy of Nîmes University Hospital in France shares insights into how this technology is evolving and what it means for clinical practice now and in the future. 3D printing, or additive manuf

Hospitals 111

Hospitals Compounding Dosage FDA 111

pharmaphorum

MARCH 21, 2024

Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is currently gaining traction in cancer immunotherapy.

111

111

Fierce Healthcare

MARCH 21, 2024

Long-term and post-acute care (LTPAC) providers play a vital role in our health system. | Continuing to improve and coordinate post-acute care can lead to higher quality and lower costs. As such, long-term and post-acute care providers are in a position to lead the way on value-based care.

111

111

European Pharmaceutical Review

MARCH 21, 2024

Can you tell us a bit about yourself and your role at Pfizer? I’m a pharmacist with an MBA and PhD. My PhD thesis is about considerations in the production and purchasing of drugs. I joined Pfizer in January 2023 as a health access specialist, after working at Clalit Health Services in Israel for almost 20 years. At Clalit, which is the second largest healthcare provider in the world, I worked in several management positions and gained a broad understanding of the needs and constraints of a heal

Packaging 110

Packaging 110